Medicinal Chemistry Research Laboratories II, Daiichi Sankyo Co., Ltd, 1-16-13, Kita-Kasai, Edogawa-ku, Tokyo 134-8630, Japan.
Bioorg Med Chem. 2009 Oct 1;17(19):6879-89. doi: 10.1016/j.bmc.2009.08.026. Epub 2009 Aug 20.
A series of novel 6-desfluoro [des-F(6)] and 6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methoxyquinolones bearing 3-(1-aminocycloalkyl)pyrrolidin-1-yl substituents at the C-7 position (1-6) was synthesized to obtain potent drugs for nosocomial infections caused by Gram-positive pathogens. The des-F(6) compounds 4-6 exhibited at least four times more potent activity against representative Gram-positive bacteria than ciprofloxacin or moxifloxacin. Among the derivatives, 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] derivative 4, which showed favorable profiles in preliminary toxicological and non-clinical pharmacokinetic studies, exhibited potent antibacterial activity against clinically isolated Gram-positive pathogens that had become resistant to one or more antibiotics.
为了获得针对革兰氏阳性病原体引起的医院获得性感染的强效药物,我们合成了一系列新型的 C-7 位带有 3-(1-氨环烷基)吡咯烷-1-基取代基的 6-去氟[去 F(6)]和 6-氟-1-[(1R,2S)-2-氟环丙-1-基]-8-甲氧基喹啉酮(1-6)。与环丙沙星或莫西沙星相比,去 F(6)化合物 4-6 对代表性革兰氏阳性菌的活性至少高出四倍。在这些衍生物中,7-[(3R)-3-(1-氨环丙基)吡咯烷-1-基]衍生物 4 在初步毒理学和非临床药代动力学研究中表现出良好的特性,对临床分离的对一种或多种抗生素耐药的革兰氏阳性病原体具有强大的抗菌活性。